Key facts
- This page summarizes Aaron Gorovitz's Form 4 filing for NRX Pharmaceuticals, Inc. (NRXP).
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 10 Jun 2021, 18:47.
Aaron Gorovitz - 24 May 2021 Form 4 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)
- Reporting relationship
- Director
- Issuer ticker
- NRXP
- Reported as of
- 24 May 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jun 2021, 18:47:12 UTC
- Next SEC filing
- 22 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Aaron Gorovitz
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Aaron Gorovitz filed Form 4 for NRX Pharmaceuticals, Inc. (NRXP) on 10 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NRXP
transaction
Common Stock
Award
- Transaction value
- Shares
- +8,336
- Change %
- Price
- Shares after
- 8,336
- Date
- 24 May 2021
- Ownership
- By Trust
- Footnotes
- F1, F2, F3
NRXP
transaction
Common Stock
Award
- Transaction value
- Shares
- +8,336
- Change %
- Price
- Shares after
- 8,336
- Date
- 24 May 2021
- Ownership
- By Trust
- Footnotes
- F1, F2, F4
NRXP
transaction
Common Stock
Award
- Transaction value
- Shares
- +8,336
- Change %
- Price
- Shares after
- 8,336
- Date
- 24 May 2021
- Ownership
- By Trust
- Footnotes
- F1, F2, F5
NRXP
transaction
Common Stock
Award
- Transaction value
- Shares
- +16,678
- Change %
- Price
- Shares after
- 16,678
- Date
- 24 May 2021
- Ownership
- By spouse
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the "Merger Agreement") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the "Issuer"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and NeuroRx, Inc. ("NeuroRx"), Merger Sub merged with and into NeuroRx (the "Merger"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the "Earnout Shares") and Earnout Cash (as defined in the Merger Agreement).
Footnote F2
The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the "Earnout Shares Milestone"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger.
Footnote F3
Held by the Samuel David Gorovitz 2017 Irrevocable Trust of which the Reporting Person is trustee.
Footnote F4
Held by the Jeremy Paul Gorovitz 2017 Irrevocable Trust of which the Reporting Person is trustee.
Footnote F5
Held by the Marisa Shey Gorovitz 2017 Irrevocable Trust of which the Reporting Person is trustee.